Evidence map›Paper›PMID 40662666›Full record

ArticleMicrobiology spectrum2025

Adaptive laboratory-evolved MRSA with PPEF manifests cross-susceptibility to oxacillin and hypersensitivity to ciprofloxacin.

Vikas Maurya, Raja Singh, Shruti Kutmutia, Bibha Chaudhary, Souvik Bhattacharjee, Vibha Tandon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vikas Maurya *Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.
Raja Singh *Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
Shruti KutmutiaBacalt Biosciences Private Limited, Bengaluru, Karnataka, India.
Bibha ChaudharyInstitute of Bioinformatics and Applied Biotechnology, Bengaluru, India.
Souvik BhattacharjeeSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.
Vibha TandonSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.ORCID 0000-0001-6146-937X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging resistance to current antibiotics is a global threat to human health. Therefore, comprehending the mechanism behind antibiotic resistance holds paramount importance. In the pursuit of finding new antibacterial agents, our group has developed a small molecule, PPEF (2'-(4-ethoxyphenyl)-5-(4-propylpiperazin-1-yl)-1H,1'H-2,5'-bibenzo(d)imidazole), having bisbenzimidazole as a pharmacophore, targeting bacterial type IA topoisomerase, a novel drug target in bacteria. We examined the emergence of mutations leading to PPEF resistance in laboratory-evolved

Indexed as

Anti-Bacterial AgentsCiprofloxacinMethicillin-Resistant Staphylococcus aureusOxacillinPiperazinesBacterial ProteinsHumansMicrobial Sensitivity TestsMutationStaphylococcal InfectionsAnti-Bacterial AgentsBacterial ProteinsCiprofloxacinOxacillinPiperazinesadaptive laboratory evolutionantimicrobial resistancenext-generation sequencingPPEF

Identifiers

PMID40662666
PMCPMC12323363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.